Pfizer-Valneva Lyme Vaccine Shows 73% Efficacy but Misses Statistical Endpoint
Pfizer and Valneva's Lyme vaccine reduced disease risk by over 70% in Phase 3 trials but missed a key statistical goal. The outcome poses regulatory challenges despite the vaccine's potential to prevent widespread Lyme disease.
· 74d ago
